000285205 001__ 285205
000285205 005__ 20260212110308.0
000285205 0247_ $$2doi$$a10.1002/ana.78066
000285205 0247_ $$2pmid$$apmid:41133969
000285205 0247_ $$2ISSN$$a0364-5134
000285205 0247_ $$2ISSN$$a1531-8249
000285205 037__ $$aDZNE-2026-00184
000285205 041__ $$aEnglish
000285205 082__ $$a610
000285205 1001_ $$aLindenborn, Paula$$b0
000285205 245__ $$aCombination of Serum Neurofilament Light Chain and Serum Cardiac Troponin T as Biomarkers Improves Diagnostic Accuracy in Amyotrophic Lateral Sclerosis.
000285205 260__ $$aHoboken, NJ$$bWiley-Blackwell$$c2026
000285205 3367_ $$2DRIVER$$aarticle
000285205 3367_ $$2DataCite$$aOutput Types/Journal article
000285205 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1770890475_9052
000285205 3367_ $$2BibTeX$$aARTICLE
000285205 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000285205 3367_ $$00$$2EndNote$$aJournal Article
000285205 520__ $$aWe aimed to evaluate the clinical utility of serum neurofilament light chain (sNfL) and cardiac troponin T (cTnT) in amyotrophic lateral sclerosis (ALS) and assess whether their combination improves diagnostic accuracy.We retrospectively analyzed 293 ALS patients, 85 neurodegenerative disease controls, and 29 healthy controls. A validation cohort of 501 ALS patients was analyzed to confirm reproducibility of the results. Receiver operating characteristic (ROC) curve analysis was performed for sNfL, cTnT, and their combination, and the area under the curve (AUC) was compared across groups. An ALS-specific cTnT cut-off of 8.35ng/L was determined using the Youden index and applied in subgroup analyses, in which 'biomarker-negative' ALS patients were compared to 'biomarker-positive' patients regarding disease duration and progression.sNfL showed excellent performance in discriminating ALS patients from healthy controls (AUC = 0.94), but only moderate performance in discriminating neurodegenerative disease controls (AUC = 0.82). Combining sNfL and cTnT improved diagnostic accuracy for ALS over neurodegenerative controls, with an AUC of 0.90, whereas cTnT alone showed an AUC of 0.77. The validation cohort showed similar AUCs. 'Biomarker-negative' ALS patients had a longer disease duration (73.0 vs 18.0 months, p = 0.0003) and a lower progression rate (0.19 vs 0.70 points per months, p < 0.0001) than 'biomarker-positive' patients.Although sNfL alone performs well in distinguishing ALS from healthy controls, repurposing cTnT for ALS provides additional value in discriminating ALS from disease controls. The combination of sNfL and cTnT improves diagnostic accuracy and may help identify prognostically distinct ALS subgroups. ANN NEUROL 2026;99:408-417.
000285205 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000285205 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000285205 7001_ $$aFabian, Rachel$$b1
000285205 7001_ $$aGrehl, Torsten$$b2
000285205 7001_ $$aNazlican, Huelya$$b3
000285205 7001_ $$aMeyer, Thomas$$b4
000285205 7001_ $$0P:(DE-2719)9000485$$aBernsen, Sarah$$b5$$eLast author$$udzne
000285205 7001_ $$0P:(DE-2719)9001116$$aWeydt, Patrick$$b6$$eLast author
000285205 773__ $$0PERI:(DE-600)2037912-2$$a10.1002/ana.78066$$gVol. 99, no. 2, p. 408 - 417$$n2$$p408 - 417$$tAnnals of neurology$$v99$$x0364-5134$$y2026
000285205 8564_ $$uhttps://pub.dzne.de/record/285205/files/DZNE-2026-00184.pdf$$yRestricted
000285205 8564_ $$uhttps://pub.dzne.de/record/285205/files/DZNE-2026-00184.pdf?subformat=pdfa$$xpdfa$$yRestricted
000285205 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000485$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000285205 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9001116$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000285205 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000285205 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-11-06$$wger
000285205 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2025-11-06$$wger
000285205 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN NEUROL : 2022$$d2025-11-06
000285205 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-11-06
000285205 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-11-06
000285205 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-11-06
000285205 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-11-06
000285205 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-11-06
000285205 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2025-11-06
000285205 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-11-06
000285205 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-11-06
000285205 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-11-06
000285205 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-11-06
000285205 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-11-06
000285205 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-11-06
000285205 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bANN NEUROL : 2022$$d2025-11-06
000285205 9201_ $$0I:(DE-2719)1011001$$kClinical Research (Bonn)$$lClinical Research Coordination$$x0
000285205 9201_ $$0I:(DE-2719)5000075$$kAG Radbruch$$lClinical Neuroimaging$$x1
000285205 980__ $$ajournal
000285205 980__ $$aEDITORS
000285205 980__ $$aVDBINPRINT
000285205 980__ $$aI:(DE-2719)1011001
000285205 980__ $$aI:(DE-2719)5000075
000285205 980__ $$aUNRESTRICTED